To verify the specific effects of rosiglitazone (Rosi) on glucose and insulin tolerance, the PPARγ antagonist (GW9662) and PPARα antagonist (GW6471) were used during IR at 32-weeks old and DM at 48-weeks old. This evidence concerns the gene INS and diabetes mellitus.